Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Ketorolac

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoropack

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoroz

    Ketorolac Tromethamine
    IM/IV Injection 30 mg/ml Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoroz

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoseem

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoshot

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoshot

    Ketorolac Tromethamine
    IM/IV Injection 30 mg/ml Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketosma

    Ketotifen Fumarate (Oral)
    Tablet 1 mg Allopathic Cromoglycate & related drugs

    Indications

    Asthma prophylaxis

    Indication detailsView
    Ketotifen is indicated in the following conditions-
    • For the prophylactic treatment of bronchial asthma.
    • Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.
    • For alleviating the complications of itching, pain and tenderness associated with neurofibroma.
    • Symptomatic treatment of allergy such as hayfever, urticaria.
    Therapeutic classView
    Cromoglycate & related drugs
    PharmacologyView
    Ketotifen has anti-allergic properties and has been used similarly, to sodium chromoglycate in the prophylactic treatment of asthma. It also has the properties of an antihistamine. Ketotifen possesses marked anti-anaphylactic properties and is effective in preventing an asthmatic attacks. Ketotifen exerts as sustained inhibitory effect on histamine reactions, which can be clearly dissociated from its anti-anaphylactic properties. Experimental investigations in asthmatic subjects have shown that Ketotifen is as effective orally as a selective mast cell stabilizer administered by inhalation. Antihistamines were ineffective in those tests. The effectiveness of Ketotifen has been studied in long-term clinical trials. Asthma attacks were reduced in number, severity and duration and in some cases, the patients were completely freed from attacks. Progressive reduction of corticosteroids and/or bronchodilators was also possible. The prophylactic activity of Ketotifen may take several weeks to become fully established. Ketotifen will not abort established attacks of asthma.
    DosageView
    Adults: 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases.

    Children above 3 years: 1 mg twice daily with food. Patients known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician.

    Use in elderly: Same as adult dose or as advised by the physician.
    Side effectsView
    Drowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment but usually disappear spontaneously after a few days.
    ContraindicationsView
    A reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided. Although there is no evidence of any teratogenic effect, recommendations for Ketotifen in pregnancy or when breast feeding can not be given.
    PrecautionsView
    It is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patient. If inter current infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patients should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohol.
    InteractionsView
    Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohols. A reversible fall in the platelet count has been observed in a few patients receiving Tifen concomitantly with oral antidiabetic agents and it has been suggested that this combination should therefore be avoided.
    Pregnancy & lactationView
    Although there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.
    Overdose effectsView
    The reported features of overdosage include confusion, drowsiness, headache, bradycardia, respiratory depression etc. should be watched for. Elimination of the drug with gastric lavage or emessis is recommended. Otherwise, general supportive treatment is all that is required shall be instituted.
    StorageView
    Store in a cool and dry place, protect from light. Keep out of the reach of children.

    Ketosma

    Ketotifen Fumarate (Oral)
    Syrup 1 mg/5 ml Allopathic Cromoglycate & related drugs

    Indications

    Asthma prophylaxis

    Indication detailsView
    Ketotifen is indicated in the following conditions-
    • For the prophylactic treatment of bronchial asthma.
    • Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.
    • For alleviating the complications of itching, pain and tenderness associated with neurofibroma.
    • Symptomatic treatment of allergy such as hayfever, urticaria.
    Therapeutic classView
    Cromoglycate & related drugs
    PharmacologyView
    Ketotifen has anti-allergic properties and has been used similarly, to sodium chromoglycate in the prophylactic treatment of asthma. It also has the properties of an antihistamine. Ketotifen possesses marked anti-anaphylactic properties and is effective in preventing an asthmatic attacks. Ketotifen exerts as sustained inhibitory effect on histamine reactions, which can be clearly dissociated from its anti-anaphylactic properties. Experimental investigations in asthmatic subjects have shown that Ketotifen is as effective orally as a selective mast cell stabilizer administered by inhalation. Antihistamines were ineffective in those tests. The effectiveness of Ketotifen has been studied in long-term clinical trials. Asthma attacks were reduced in number, severity and duration and in some cases, the patients were completely freed from attacks. Progressive reduction of corticosteroids and/or bronchodilators was also possible. The prophylactic activity of Ketotifen may take several weeks to become fully established. Ketotifen will not abort established attacks of asthma.
    DosageView
    Adults: 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases.

    Children above 3 years: 1 mg twice daily with food. Patients known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician.

    Use in elderly: Same as adult dose or as advised by the physician.
    Side effectsView
    Drowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment but usually disappear spontaneously after a few days.
    ContraindicationsView
    A reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided. Although there is no evidence of any teratogenic effect, recommendations for Ketotifen in pregnancy or when breast feeding can not be given.
    PrecautionsView
    It is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patient. If inter current infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patients should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohol.
    InteractionsView
    Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohols. A reversible fall in the platelet count has been observed in a few patients receiving Tifen concomitantly with oral antidiabetic agents and it has been suggested that this combination should therefore be avoided.
    Pregnancy & lactationView
    Although there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.
    Overdose effectsView
    The reported features of overdosage include confusion, drowsiness, headache, bradycardia, respiratory depression etc. should be watched for. Elimination of the drug with gastric lavage or emessis is recommended. Otherwise, general supportive treatment is all that is required shall be instituted.
    StorageView
    Store in a cool and dry place, protect from light. Keep out of the reach of children.

    Ketosteril

    Amino Acid + Calcium
    Tablet Allopathic Drugs used in chronic kidney dialysis

    Indications

    Deficient protein metabolism

    Indication detailsView
    Prevention and therapy of damages due to faulty or deficient protein metabolism in chronic renal insufficiency in connection with limited protein in food of 40 g/day (for adults) ie, generally in patients with a glomerular filtration rate (GFR) 25 mL/minutes.
    Therapeutic classView
    Drugs used in chronic kidney dialysis
    PharmacologyView
    This tablet allows the intake of essential amino acids while minimising the amino-nitrogen intake. Following absorption, the keto- and hydroxy-analogues are transaminated to the corresponding essential amino acids by taking nitrogen from non-essential amino acids, therby decreasing the formation of urea by re-using the amino group. Hence, the accumulation of uraemic toxins is reduced. Keto and hydroxy acids do not induce hyperfiltration of the residual nephrons. Ketoacid containing supplements exert positive effect on renal hyper phosphataemia and secondary hyperparathyroidism. Moreover, renal osteodystrophy may be improved. The use of this tablet in combination with a very low protein diet allows to reduce nitrogen intake while preventing the deleterious consequences of inadequate dietary protein intake and malnutrition.
    DosageView
    Adults (70 kg body weight): If not otherwise prescribed, take 4 to 8 tablets three times a day during meals. Swallow whole and must not be chewed. Ingestion during meals facilitates proper absorption and the metabolisation into the corresponding amino acids.

    Duration of Application: This tablets are given as long as the glomerular filtration rate (GFR) is between 5 and about 15 mL/minute. Simultaneously food should contain 40 g/day protein or less (adults).
    Side effectsView
    Hypercalcemia may develop. In this case it is recommended to decrease Vitamin D intake. If hypercalcaemia persists, reduce the dosage of this tablet as well as other source of calcium. The serum calcium level should be monitored regularly. Ensure sufficient calorie intake. No experience has been gained so far with the administration in paediatric patients.
    ContraindicationsView
    Hypersensitivity to the active substances or to any of the excipients. Hypercalcaemia. Disturbed amino acid metabolism.
    PrecautionsView
    • The serum calcium level should be monitored regularly.
    • Ensure sufficient calorie intake.
    • In the presence of hereditary phenylketonuria, attention should be given to the fact that this tablet contains phenylalanine.
    • Monitoring of the serum phosphate levels is needed in case of concomitant administration of aluminium hydroxide.
    InteractionsView
    • Concomitant administration of calcium-containing drugs may cause or aggravate elevated serum calcium levels.
    • Drugs that form hardly soluble compounds with calcium (e.g. tetracyclines, quinolines such as ciprofloxacin and norfloxacin as well as drugs containing iron, fluoride or estramustine) should not be taken at the same time with this tablet to avoid disturbed absorption of the active substances. An interval of at least two hours should elapse between the ingestion of this tablet and these drugs.
    • The susceptibility to cardioactive glycosides, and hence the risk for arrhythmia will increase if this tablet produces elevated serum calcium levels.
    • Uraemic symptoms improve under therapy with this tablet. Thus, in case of aluminium hydroxide administration, the dose of this drug has to be reduced if necessary. Serum phosphate levels should be monitored for a decrease.
    Pregnancy & lactationView
    There are no adequate data from the use of this tablet in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women. No experience has been made so far with the use during lactation. No case of overdose has been reported.
    StorageView
    Do not store above 30° C. Store in the original package and keep the blisters tightly closed to protect contents from moisture.

    Ketotab

    Ketoconazole (Tablet)
    Tablet 200 mg Allopathic Drugs for subcutaneous and mycoses

    Indications

    Vaginitis

    Indication detailsView
    Treatment of superficial and deep mycoses:
    • Infections of the skin, hair and nails by dermatophytes and/or yeasts (dermatomycosis, onychomycosis, perionyxis, pityriasis versicolor, chronic mucocutaneous candidiasis etc.) especially when topical treatment is difficult or not very effective, owing to involvement of large skin surfaces or to lesions affecting deeper dermal layers, nails and hairs
    • Yeast infection of the mouth (oral thrush, perleche) and the gastrointestinal tract
    • Vaginal candidiasis, especially chronic recurrent cases or cases responding poorly to topcial treatment
    • Systemic mycotic infections such as systemic candidiasis, paracoccidioidomycosis, histoplasmosis, coccidioidomycosis etc.
    Maintenance treatment to prevent recurrence in systemic mycotic infections and in chronic mucocutaneous candidiasis.

    Prophylactic treatment to prevent mycotic infection in patients with reduced host defenses, e.g., patients with cancer, organ transplant and burns.
    Therapeutic classView
    Drugs for subcutaneous and mycoses
    PharmacologyView
    Ketoconazole interferes with biosynthesis of triglycerides and phopholipids by blocking fungal CYP450, thus altering cell membrane permeability in susceptible fungi. It also inhibits other fungal enzymes resulting in the accumulation of toxic concentrations of hydrogen peroxide.
    DosageView
    Vaginal candidiasis: 1 tablet (200 mg) tablet twice daily for 5 days.

    All other indications: 1 tablet (200 mg) once daily until at least one week after the symptoms have disappeared and the cultures have become negative.
    AdministrationView
    Ketoconazole should be taken at meal times for maximal resorption. Because resorption depends on intact gastric activity, the concomitant treatment with agents that reduce gastric secretion (anticholinergic drugs, antacids, H2 blockers) should be avoided. When indicated, such drugs should be taken not earlier than two hours after ketoconazole. If clinical responsiveness is insufficient within the expected time, the dose of ketoconazole may be doubled (400 mg once daily).
    Side effectsView
    Ketoconazole is very well tolerated. Nausea and itching may occasionally occur. In some patients, an idosyncratic liver reaction may occur (incidence 1:10000).
    ContraindicationsView
    Ketoconazole is contraindicated in pregnancy and in patients with acute liver pathology.
    PrecautionsView
    In patients with a previous history of liver disease, liver enzyme levels should be monitored during treatment. When patients develop symptoms indicative of liver reaction, such as nausea or fatigue, accompanied with pale faeces, dark urine or jaundice, Ketoconazole therapy should be stopped immediately
    InteractionsView
    Reduced absorption with antimuscarinics, antacids, H2-blockers, PPIs and sucralfate. Reduced plasma concentrations with rifampicin, isoniazid, efavirenz, nevirapine, phenytoin. May also reduce concentrations of isoniazid and rifampicin. May reduce efficacy of oral contraceptives. May increase serum levels of CYP3A4 substrates e.g. digoxin, oral anticoagulants, sildenafil, tacrolimus.
    Pregnancy & lactationView
    Pregnancy category C. There is no adequate and well controlled studies in pregnant women. Ketoconazole Tablets should not be used during pregnancy and lactation.
    Duration of treatmentView
    • Pityriasis versicolor: 1 to 6 weeks
    • Dermatomycoses: 2 to 8 weeks
    • Onychomycoses: 1 to 12 months
    • Mycoses of hair and scalp: 1 to 2 months
    • Chronic mucocutaneous candidiasis : 1 to 12 months
    • Oral mycoses: 5 to 10 days
    • Systemic candidiasis: 1 to 2 months
    • Paracoccidioidomycosis,histoplasmosis
    • and other systemic mycosis: 1 month to 2 years
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Ketotif

    Ketotifen Fumarate (Oral)
    Tablet 1 mg Allopathic Cromoglycate & related drugs

    Indications

    Asthma prophylaxis

    Indication detailsView
    Ketotifen is indicated in the following conditions-
    • For the prophylactic treatment of bronchial asthma.
    • Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.
    • For alleviating the complications of itching, pain and tenderness associated with neurofibroma.
    • Symptomatic treatment of allergy such as hayfever, urticaria.
    Therapeutic classView
    Cromoglycate & related drugs
    PharmacologyView
    Ketotifen has anti-allergic properties and has been used similarly, to sodium chromoglycate in the prophylactic treatment of asthma. It also has the properties of an antihistamine. Ketotifen possesses marked anti-anaphylactic properties and is effective in preventing an asthmatic attacks. Ketotifen exerts as sustained inhibitory effect on histamine reactions, which can be clearly dissociated from its anti-anaphylactic properties. Experimental investigations in asthmatic subjects have shown that Ketotifen is as effective orally as a selective mast cell stabilizer administered by inhalation. Antihistamines were ineffective in those tests. The effectiveness of Ketotifen has been studied in long-term clinical trials. Asthma attacks were reduced in number, severity and duration and in some cases, the patients were completely freed from attacks. Progressive reduction of corticosteroids and/or bronchodilators was also possible. The prophylactic activity of Ketotifen may take several weeks to become fully established. Ketotifen will not abort established attacks of asthma.
    DosageView
    Adults: 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases.

    Children above 3 years: 1 mg twice daily with food. Patients known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician.

    Use in elderly: Same as adult dose or as advised by the physician.
    Side effectsView
    Drowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment but usually disappear spontaneously after a few days.
    ContraindicationsView
    A reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided. Although there is no evidence of any teratogenic effect, recommendations for Ketotifen in pregnancy or when breast feeding can not be given.
    PrecautionsView
    It is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patient. If inter current infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patients should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohol.
    InteractionsView
    Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohols. A reversible fall in the platelet count has been observed in a few patients receiving Tifen concomitantly with oral antidiabetic agents and it has been suggested that this combination should therefore be avoided.
    Pregnancy & lactationView
    Although there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.
    Overdose effectsView
    The reported features of overdosage include confusion, drowsiness, headache, bradycardia, respiratory depression etc. should be watched for. Elimination of the drug with gastric lavage or emessis is recommended. Otherwise, general supportive treatment is all that is required shall be instituted.
    StorageView
    Store in a cool and dry place, protect from light. Keep out of the reach of children.

    Ketotifen

    Ketotifen Fumarate (Ophthalmic)
    Ophthalmic Solution 0.03% Allopathic Ophthalmic Non-Steroid drugs

    Indications

    Watery eye

    Indication detailsView
    Ketotifen eye drop is indicated for the treatment of signs & symptoms (itchy, watery, red & swollen eyes and eyelids) of allergic conjunctivitis including vernal kerato-conjunctivitis, vernal-keratitis, blepharitis, blepharo-conjunctivitis, and giant papillary conjunctivitis.
    Therapeutic classView
    Ophthalmic Non-Steroid drugs
    PharmacologyView
    Ketotifen is a potent anti-allergic substance possessing a powerful and sustained non-competitive histamine (H1) receptor blocking property. Ketotifen inhibits the release of mediators (e.g histamine, leukotrienes and prostaglandins) from cells responsible for type-(I) allergic reactions. Ketotifen also stabilizes mast cells, decreases chemotaxis, activation of degranulation of eosinophils.
    DosageView
    Adults and children 3 years and older: 1 drop in the affected eye(s) twice daily, every 8-12 hours, not more than twice per day.

    Children under 3 years of age: Consult with a doctor.
    Side effectsView
    Common side effects are burning, stinging, punctate corneal epithelial erosion, Blurring of vision upon drug instillation, dry eyes, eyelid disorder, conjunctivitis, eye pain, photophobia, subconjunctival haemorrhage.
    ContraindicationsView
    Hypersensitivity to Ketotifen or any of the components
    PrecautionsView
    The formulation of Ketotifen 0.025% eye drops contains benzalkonium chloride as a preservative, which may be deposited in soft contact lenses; therefore this eye drops should not be instilled while the patient is wearing lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.
    InteractionsView
    If Ketotifen eye drops is used concomitantly with other eye medications there must be an interval of at least 5 minutes between the two medications.
    Pregnancy & lactationView
    There are no adequate data from the use of ketotifen eye drops in pregnant women. Systemic levels after ocular administration are much lower than after oral use. Caution should be exercised when prescribing to pregnant women. Although animal data following oral administration show excretion into breast milk, topical administration to humans is unlikely to produce detectable quantities in breast milk. ketotifen 0.25% eye drops can be used during lactation.
    Overdose effectsView
    No case of overdose has been reported. Oral ingestion of the contents of a 5 ml bottle would be equivalent to 1.25 mg of Ketotifen which is 60% of a recommended oral daily dose for a 3 years old child. Clinical results have shown no serious signs or symptoms after oral ingestion of up to 20 mg of Ketotifen.
    StorageView
    Store in a cool and dry place protected from light and moisture. Keep out of reach of children. Do not touch the dropper tip to any surface since this may contaminate the solution. Do not use after 30 days of first opening.

    Ketotifen

    Ketotifen Fumarate (Oral)
    Tablet 1 mg Allopathic Cromoglycate & related drugs

    Indications

    Asthma prophylaxis

    Indication detailsView
    Ketotifen is indicated in the following conditions-
    • For the prophylactic treatment of bronchial asthma.
    • Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.
    • For alleviating the complications of itching, pain and tenderness associated with neurofibroma.
    • Symptomatic treatment of allergy such as hayfever, urticaria.
    Therapeutic classView
    Cromoglycate & related drugs
    PharmacologyView
    Ketotifen has anti-allergic properties and has been used similarly, to sodium chromoglycate in the prophylactic treatment of asthma. It also has the properties of an antihistamine. Ketotifen possesses marked anti-anaphylactic properties and is effective in preventing an asthmatic attacks. Ketotifen exerts as sustained inhibitory effect on histamine reactions, which can be clearly dissociated from its anti-anaphylactic properties. Experimental investigations in asthmatic subjects have shown that Ketotifen is as effective orally as a selective mast cell stabilizer administered by inhalation. Antihistamines were ineffective in those tests. The effectiveness of Ketotifen has been studied in long-term clinical trials. Asthma attacks were reduced in number, severity and duration and in some cases, the patients were completely freed from attacks. Progressive reduction of corticosteroids and/or bronchodilators was also possible. The prophylactic activity of Ketotifen may take several weeks to become fully established. Ketotifen will not abort established attacks of asthma.
    DosageView
    Adults: 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases.

    Children above 3 years: 1 mg twice daily with food. Patients known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician.

    Use in elderly: Same as adult dose or as advised by the physician.
    Side effectsView
    Drowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment but usually disappear spontaneously after a few days.
    ContraindicationsView
    A reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided. Although there is no evidence of any teratogenic effect, recommendations for Ketotifen in pregnancy or when breast feeding can not be given.
    PrecautionsView
    It is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patient. If inter current infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patients should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohol.
    InteractionsView
    Ketotifen may potentiate the effects of sedatives, hypnotics, antihistamines and alcohols. A reversible fall in the platelet count has been observed in a few patients receiving Tifen concomitantly with oral antidiabetic agents and it has been suggested that this combination should therefore be avoided.
    Pregnancy & lactationView
    Although there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.
    Overdose effectsView
    The reported features of overdosage include confusion, drowsiness, headache, bradycardia, respiratory depression etc. should be watched for. Elimination of the drug with gastric lavage or emessis is recommended. Otherwise, general supportive treatment is all that is required shall be instituted.
    StorageView
    Store in a cool and dry place, protect from light. Keep out of the reach of children.

    Ketovir

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoxguard

    Ketorolac Tromethamine
    IM/IV Injection 30 mg/ml Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketoxguard

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketozol

    Ketoconazole (Shampoo)
    Shampoo 2% Allopathic Drugs for subcutaneous and mycoses

    Indications

    Seborrhoeic dermatitis

    Indication detailsView
    ketoconazole 2% shampoo is indicated for the treatment and prophylaxis of infections in which the yeast Malassezia (previously called Pityrosporum) is involved, such as pityriasis versicolor (localized), seborrhoeic dermatitis and pityriasis capitis (dandruff).
    Therapeutic classView
    Drugs for subcutaneous and mycoses
    PharmacologyView
    Ketoconazole 2% shampoo is a broad spectrum imidazole-dioxolane, synthetic antifungal agent which inhibits the in vitro growth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseum and Epidermophyton floc-cosum; yeasts: Candida albicans, Malassezia ovale (Pityrosporum ovale) and C. tropicalis; and the organism responsible for tinea versicolor, Malassezia furfur (Pityrosporum orbiculare).
    DosageView
    The affected areas of the skin or the scalp should be washed with ketoconazole 2% shampoo, which should be left on the skin/scalp for 3 to 5 minutes before rinsing.
    Treatment:
    • Pityriasis versicolor: Once daily for 5 days.
    • Seborrhoeic dermatitis and pityriasis capitis: Twice weekly for 2 to 4 weeks.
    Prophylaxis:
    • Pityriasis versicolor: Once daily for 3 days during a single treatment course before the summer.
    • Seborrhoeic dermatitis and pityriasis capitis: Once every 1 or 2 weeks
    Side effectsView
    Topical treatment with ketoconazole shampoo 2% is generally well tolerated. As with other shampoos, a local burning sensation, itching or contact dermatitis (due to irritation or allergy) may occur on exposed areas. Oily and dry hair have been reported rarely with the use of ketoconazole shampoo 2%.
    ContraindicationsView
    Contraindicated in patients with known hypersensitivity to ketoconazole.
    PrecautionsView
    In patients who have been on prolonged treatment with topical corticosteroids, it is recommended that the steroid therapy be gradually withdrawn over a period of 2 to 3 weeks, while using ketoconazole shampoo 2%, to prevent any potential rebound effect. Increased hair shedding is often associated with seborrhoeic dermatitis and dandruff, and has been rarely reported with the use of ketoconazole shampoo 2%. Avoid contact with the eyes. If the shampoo should get into the eyes, they should be bathed with water.
    InteractionsView
    No information was found for the Shampoo form of Ketoconazole.
    Pregnancy & lactationView
    Since ketoconazole is not absorbed through the skin after topical application, pregnancy and lactation are not a contraindication for the use of ketoconazole shampoo 2%.
    Overdose effectsView
    Not expected as ketoconazole shampoo 2% is intended for external use only. In the event of accidental ingestion, only supportive measures should be carried out. To avoid aspiration, emesis or gastric lavage should not be performed.
    StorageView
    Store in a cool and dry place, protected from light.

    Ketromin

    Ketorolac Tromethamine
    IM/IV Injection 60 mg/2 ml Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ketromin

    Ketorolac Tromethamine
    IM/IV Injection 30 mg/ml Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.